Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod gel to enhance Hepatitis B vaccine response
NCT00175435Phase 2Completed
- Sponsor
- University of British Columbia
- Start
- Aug 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of resiquimod in hepatitis B (HBV) (3 arms), sponsored by University of British Columbia. Primary endpoint: Hepatitis B antibody and T-cell response at 30 days. Started Aug 2005; status: completed.
02
Drugs
resiquimod
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00175435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00175435.